HDAC inhibitor has been receiving attention as a new drug with strong anti-cancer activity in preclinical and clinical trials. In it, two substances resminostat and givinostat known as HDAC inhibitors have biological activity in the treatment of cancer. But there are no published documents on biological activity and specific inhibitory ability on HDAC8 enzyme. Therefore, in this study, we use the in silico method by integrated software to conduct molecular docking, evaluate the interaction and inhibition of two active substances resminostat and givinostat on HDAC8 enzyme (ID: 1T67) aims to
identify potential chemical frameworks for selective inhibition of HDAC8, as a basis for development of similar derivatives that contribute to the search for potential anticancer substances.